Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
Active, not recruiting · Phase 2 · NCT03539536
Conditions: Non-small Cell Lung Cancer
At a glance
- Research payments reported, 2025
- $112,755
- U.S. investigators named
- 15
- Sites paid
- 12
- Planned or actual enrollment
- 270
About the trial
- Sponsor
- AbbVie
- Tested
- Telisotuzumab vedotin (drug)
- Dates
- Started 2018-10-10; completion 2026-08
- Results posted
- Not yet
This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that overexpress c-Met (c-Met+) best suited for telisotuzumab vedotin therapy in the second line or third line setting (Stage 1) and then to expand the group(s) to further evaluate efficacy in the selected population(s) (Stage 2). After the Stage 2 global enrollment is completed, an additional cohort at an alternate dose level will evaluate the safety and efficacy of telisotuzumab vedotin (Stage 3).
From ClinicalTrials.gov, last updated 2025-11-05. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $112,755 in research payments for this study in 2025 (36 payments).
Products named: Emrelis
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Timothy E. Byun, MD Hematology & Oncology · Orange, CA
- Jonathan W. Goldman, M.D. Hematology & Oncology · Santa Monica, CA
- Robert M. Jotte, MD Hematology & Oncology · Lone Tree, CO
- George R. Simon, MD Medical Oncology · Celebration, FL
- Nisha A. Mohindra, MD Medical Oncology · Chicago, IL
- James A. Wallace Medical Oncology · Chicago, IL
- Victorine V. Muse, MD Radiology · Boston, MA
- Danielle M. Richman, M.D., M.S. Radiology · Boston, MA
- Aaron S. Mansfield, MD Medical Oncology · Rochester, MN
- Atul Kumar, MD, PHD Medical Oncology · Albuquerque, NM
- William H. Moore, M.D. Radiology · Setauket, NY
- Michael J. Reiter, D.O. Radiology · Stony Brook, NY
- Mohammad A. Alnsour, MD Hematology & Oncology · Perrysburg, OH
- Alan C. Gowan, D.O. Medical Oncology · Temple, TX
- Navanshu Arora, MD Medical Oncology · Renton, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Resnick Neuropsychiatric Hospital at UCLA, CA $85,469
- Rocky Mountain Cancer Centers LLP $5,554
- Bon Secours Mercy Health Inc $4,566
- Northwestern University $3,955
- Mayo Clinic $3,150
- Ingalls Memorial Hospital, IL $2,200
- Baylor Research Institute $2,179
- St Joseph Hospital the Center for Cancer Prevention and Treatment Orange Ca $2,028
- Sbq Radiology PLLC $1,520
- Adventhealth Orlando, FL $1,311
- Valley Medical Center, WA $500
- New Mexico Cancer Care Alliance $324
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.